Our approach to primary refractory AML takes into account patient eligibility for allogeneic HSCT and salvage chemotherapy, clinical trial availability, and molecular mutation status.
Abbreviations: AML, acute myeloid leukemia; HLA, human leukocyte antigen; FLT3-ITD, fms-like tyrosine kinase 3-internal tandem duplication; HSCT, hematopoietic stem cell transplantation; HMA, hypomethylating agent; LDAC, low-dose cytarabine